Table 1.
Details of treatment before allogeneic hematopoietic cell transplantation
| Induction therapy | Consolidation therapy | ||
|---|---|---|---|
| Case 1 | Initial treatment | Daunorubicin (50 mg/m2/day, days 1-5), AraC (100 mg/m2/day, days 1-7) | 3 cycles of high-dose AraC (4,000 mg/m2/day, days 1-5) |
| First relapse (4 months after the last therapy) | Idarubicin (12 mg/m2/day, days 1-3) AraC (100 mg/m2/day, days 1-7), gilteritinib (120 mg/body, days 3-20, 18 days) | 1 cycle of high-dose AraC (4,000 mg/m2/day, days 1-5) | |
| Case 2 | Initial treatment | 2 cycles of idarubicin (12 mg/m2/day, days 1-3), AraC (100 mg/m2/day, days 1-7) | |
| Salvage therapy | MEC therapy: mitoxantrone (6.8 mg/m2/day, days 1-3), etoposide (85 mg/m2/day, days 1-5), and AraC (85 mg/m2/day, days 1-5) | ||
| first relapse (6 months after the last therapy) | FLAG therapy: fludarabine (30 mg/m2/day, days 1-5), AraC (2,000 mg/m2/day, days 1-5), and granulocyte colony stimulating factor (G-CSF), gilteritinib (120 mg/body, days 11-36, 26 days) | ||
| Case 3 | Initial treatment | Idarubicin (12 mg/m2/day, days 1-3) and AraC (100 mg/m2/day, days 1-7) | |
| Salvage therapy | MEC therapy: mitoxantrone (5.6 mg/m2/day, days 1-3), etoposide (70 mg/m2/day, days 1-5), and AraC (70 mg/m2/day, days 1-7), gilteritinib (120 mg/body, days 8-26, 19 days) | Gilteritinib (200 mg/body, 8 days) |
AraC, Cytosine arabinoside